7^th International Conference on Telemedicine, eHealth & Health Informatics November 16-17, 2018 | Mercure Albert Park | Melbourne, Australia

Biography:

Jacob Bore is a passionate Electronics Technologist, ambitious in giving the best of my professional ability, skills, and techniques to enhance my knowledge and growth in information technology, telecommunication and healthcare industry. Jacob is well-versed in medical records systems, point-of-care (POC) applications, mobile health technology, radio frequency, satellite and mobile communication, biometric security control, packet data telecommunication, computer hardware and software repair and maintenance, electrical and electronic snstallations, web development, and Microsoft Dynamics Navision (Installation, Configuration, Financials, Development and ability to offer systems support) and Mobile Programming

Abstract:

We have been using telemedicine to increase access to specialized cancer care to remote areas with poor accessibility and lacking basic health care facility to deal with cancer care. This has been achieved through partnership with eight county governments in Kenya in terms of reducing patient travel costs through teleconsultation and virtual tumor board which have enabled health care providers in these remote areas to consult with specialist in the regional referral hospitals and health care professional training, extended specialty to all clinics and improved patient referral system with prompt treatment.

Through our telemedicine center, we have been able to hold over twenty tumor boards where we interconnect with other five major hospitals to discuss patient cases. We have also established three remote telemedicine clinics where cancer patients and care providers can consult with oncologist virtually. There many challenges that are inhibiting our advancement of access to cancer care through telemedicine and it’s not limited only to cost of funding it but also includes lack of funding to establish a reliable ICT infrastructure, lack of adequate qualified health care personnel i.e. Oncology clinical officers, nurses, pharmacists, lab technologist in remote clinics.

Biography:

Prof. A.I. Petrenko has gotten a Diploma of Engineering from Kiev Polytechnic Institute  (1957), a Diploma of Imperial College from Imperial College of London University(1960), a Candidate of Science- Degree (Ph.D) from Moscow Power Institute (1963), Doctor of Science Degree from Moscow Power Institute (1969). He was invited as a Visiting Professor to 14-th universities including California University (Berkeley),USA, 1976; Michigan State University, USA, 1991; New Jersey Institute of Technology, USA, 1995; Hong Kong University,1997; Pohang University of Science and Technology, Korea, 2000; Illnenay technical University, Germany,2005, etc.  The scope of Prof. Petrenko A. scientific activities are cloud and grid technologies, SOA and SOC, mobile medicine, web-based Design, large-scale systems, numerical algorithms, etc. His leadership in Computer Science is through publications and educational activities (25 books, 424 scientific articles, 40 patents). His one book "Algorithmic Analysis of Electronic Circuits" was translated and published in USA by Western Periodicals, San-Francisco, 1975, 618 p. and  another book “ALLTED-a Computer-Aided Engineering System for Electronic Circuit Design” was published in Australia  by UICEE(UNESCO), Melbourne,1997,204 p.

 

Abstract:

Cloud SaaS for supporting individual healthcare for asthma patients by providing the interaction of the doctor and the patient in the treatment process. It will be built as microservice system which includes:

- microservices for physical data traction (breath monitoring, heart rate);

- microservice for air pollution monitoring;

- microservice for warning user before critical state coming;

- microservice for encrypting and storing data in publicly accessible blockchain;

- containers for integration executing microservices and integration them with local PHR services.

The SaaS will consist of wearable device for air monitoring (air contents+dust sensors with Bluetooth connection module) connected to user’s smartphone which will upload collected data also from body wearable devices (wheezometer, peakflow meter, etc.) and transfer them to SaaS. Smartphone is also capable for tracking user’s breath and local detection of exacerbation of asthma and delivering recommendations based on data analysis. With advancements in technology, home telemonitoring has become an effective and reliable approach that is well accepted by patients and supports patient care at home. Mobile asthma management tools target those who suffer from asthma attacks, especially children; in order to help them avoid attack inducing allergen areas and help them better control and treat their asthma symptoms. They can help to reduce asthma attacks, which could prevent unnecessary hospital readmissions and decrease the number of hospital admissions due to preventable asthma complications. Depending on particular requirements the m-application can be scaled from the corporate (national) scale of patients care with asthma to the scale of supporting profile patients in a particular region. In addition there are possibilities to rearrange the system for supporting people with other diseases due to the system microservice architecture. Previous developments were monolithic applications, designed for a fixed HW infrastructure. The whole application has to be developed and deployed in one piece and the entire tier has to be retested and redeployed when something is changed.

We were the first who start to investigate advantages of service-oriented architecture in mobile medicine.

 

Biography:

Manuela Cesaretti is a surgeon works in the department of HPB Surgery and Liver Transplantation of Beaujon Hospital in Clichy (France) and in the department of Nanophysics of the Italian Institute of Technology in Genova (Italy). She has an expertise in liver transplantation and passion in improving methods for liver graft quality assessment.

 

Abstract:

Fast and accurate graft hepatic steatosis (HS) assessment is of primary importance for lowering liver dysfunction risks after transplantation. Despite diagnosis being recognized as challenging in the clinical literature, few efforts have been invested to develop computer-assisted solutions for HS assessment. The objective of this study is to investigate the automatic learning-based analysis of liver texture from RGB images acquired in the operating room (OR), with the goal of classifying liver grafts rejected due to high HS level. Forty RGB images of forty different donors were analyzed. Twenty images refer to accepted livers and twenty to livers that were discarded due to high HS value. The ground-truth HS diagnosis associated to each image was obtained with histopathological analysis. The images were captured with an RGB (12-megapixel) smartphone camera in the OR. Intensity-based features ( S tat 1), histogram of local binary pattern ( HLBP) and features extracted from blood tests ( B l o) were investigated. Semi-supervised multiple instance learning was exploited to perform image classification (Fig 2). With the best performing feature (HLBP + S tat 1 + B l o), the overall classification accuracy was 0.88. The achieved recall in classifying discarded grafts was 0.95. The results suggest that the proposed method is a promising strategy to develop a fully automatic solution to assist surgeons in HS assessment inside the OR.

 

Biography:

Monika Rogozinska, MPharm, PMP® is a Boston-based biopharmaceutical R&D executive. During her career, she has been developing and bringing new medicines and medical devices to market. Monika has gained interdisciplinary, global expertise in various therapeutic areas, leading R&D strategy and operation in smaller and larger biopharma. She is focused on the improvement of patients’ health and quality of their lives. She is Harvard Business School alumnus, a blogger, nature lover, and photographer. Currently, Monika provides consulting services to VC and hedge funds, assessing various pharmaceutical assets regarding development risks and scenarios, to ensure only deals of highest priority are being advanced and executed by her clients.

Abstract:

Pharmaceutical companies have been forever challenged with both rising development costs and the need to find novel ways to differentiate the candidate drugs. Recent advances in digital health (DH) technology, including wearables, in-home clinical devices, and sensors, have enabled a growing array of available data endpoints, making these devices an invaluable tool in clinical programs. The broad scope of DH includes categories such as mobile health (mHealth), health information technology (IT), wearable devices and sensors, telehealth, telemedicine, and personalized medicine. Wearable devices can measure many physiological parameters and functions, including sleep, heart rate, gait, velocity, step count, blood pressure, body temperature, oxygen saturation, electrocardiogram (ECG), glucose, or even drug adherence. They are used mostly in chronic illnesses such as congestive heart failure, hypertension, diabetes, and chronic obstructive pulmonary disease (Figure 1). As a consequence, to this progress, surging drug development costs, and the need for speed, quality, and efficiency in drug development, pharmaceutical companies prompted the search for innovative technology and solutions. Advances in digital health devices and data could allow drug developers to carry out more detailed and real-time analysis of data from clinical trials. Real-time data in clinical trials brought the potential to increase the speed at which drugs progress through clinical trials, as well as accelerating go/no-go decision-making. Although digital health remains new, there is significant optimism over how a digital revolution could transform drug development, also among the regulators who actively guide and support the industry. On the other side, the discussion about the reliability of digital devices in clinical trials continues. Standardization of measurement and validation of wearable devices need a lot of work. Most software used in wearable devices has not been validated per the FDA’s standards, and doing such will add to the cost and time for developing such devices for use in specific medical settings, such as clinical trials. Device-to-device variability could lead to challenges with data analysis. Independently, we can expect to see the adoption of these digital technologies to increase as pharmaceutical companies begin to see their significant benefits. 

Biography:

Abstract:

Health service in developing countries, according to WHO over 400million people lack one of seven essential health service ranging from pregnancy care and people mostly women and children, and such people are at a greater risk of developing other complications. [The enjoyment of the highest attainable standard of health is one of the fundamental rights of every human being without distinction of race, religion, political belief economic or social condition. Which the WHO will focus on this year. But also education matters to health,  there is a saying people with more education live longer, healthier lives than those with less or no education, I have lived almost half my life in western Africa and for almost three years in east Africa and I must say education has it say in health, organizations always focuses on providing the necessary health equipment but a big percentage of people don’t  go to the healthcare centers because of lack of proper knowledge that why a great  number of people in the villages prefer to deliver from their homes rather than going to a proper hospital, which show they don’t go for their regular antenatal checkup also